Acute Toxicity Study of Bioactive Galactomannans From Two Non-Traditional Leguminosae Sources

Fabrícia da Cunha Jácome Marques
UECE: Universidade Estadual do Ceara

Francisco Glerison da Silva Nascimento
UECE: Universidade Estadual do Ceara

Dayanne Terra Tenório Nonato
UECE: Universidade Estadual do Ceara

Amaurílio Oliveira Nogueira
UECE: Universidade Estadual do Ceara

Iásly Costa Lima
UECE: Universidade Estadual do Ceara

Olga Vale Oliveira Machado
Unichristus: Centro Universitário Christus

Ana Maria Sampaio Assreuy
UECE: Universidade Estadual do Ceara

Mário Rogério Lima Mota
UFC: Universidade Federal do Ceara

Edna Maria Camelo Chaves
UECE: Universidade Estadual do Ceara

Gislei Frota Aragão
UECE: Universidade Estadual do Ceara

Rondinelle Ribeiro Castro (✉ rondinelle.castro@uece.br)
Universidade Estadual do Ceara  https://orcid.org/0000-0002-9399-4109

Pedro Marcos Gomes Soares
UFC: Universidade Federal do Ceara

Research Article

Keywords: Polysaccharide, Safety, OECD, Caesalpinia pulcherrima, Delonix regia

DOI: https://doi.org/10.21203/rs.3.rs-514492/v1

License: ☇  This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Galactomannans from *Caesalpinia pulcherrima* (GM-CP) and *Delonix regia* (GM-DR) are being pointed as potential therapeutic agents, but systematic evaluations on their acute toxicity are yet to be reported. In order to evaluate the occurrence of systemic toxicity, groups of three female rats received oral GM-CP or GM-DR (300 mg kg\(^{-1}\)), whereas the control group received vehicle. Since lethality was absent, other groups received doses of 2,000 mg kg\(^{-1}\), which also did not cause lethality. Collection of organs and blood samples were done at day 14. Dermal toxicity of the galactomannans was also evaluated (2,000 mg kg\(^{-1}\), n=3 per group), as well both mechanical hypernociception and inflammatory cell influx after administration of GM-CP or GM-DR via intra-articular route (200 µg, n = 5 per group). At the routes and doses employed, both galactomannans did not evoke physiological / behavioral changes or skin / joint inflammation. Since the LD50 was not inferior to 2,000 mg kg\(^{-1}\), both galactomannans are in the class 5 of the Globally Harmonized System for Classification and Labelling of Chemicals.

Introduction

Galactomannans are water-soluble neutral polysaccharides found in the seed endosperm of numerous plants, particularly in the Leguminosae family. They are constituted by a (1→4) linked β-mannopyranosyl backbone partially substituted at O-6 with α-D-galactopyranosyl side groups (Meer et al. 1975; Srivastava and Kapoor 2005). Because of their high viscous water solutions, the galactomannans of *Ceratonia siliqua*, *Caesapinia spinosa*, *Cyamopsis tetragonolobus* and *Trigonella foenum-graecum* are used as emulsion stabilizers in the food, cosmetic and pharmaceutical industries (Prajapati et al. 2013; Johnson et al. 2015). Despite of the galactomannans intake be conventionally assumed as safe, few systematic studies report the acute toxicology of such polysaccharides, especially those obtained from non-traditional sources (Pawar and Lalith 2015; Suryawanshi et al. 2015; Deshpande et al. 2016).

The Leguminosae species *Caesalpinia pulcherrima* (L.)Sw. and *Delonix regia* (Bojer ex Hook.)Raf. are native from Central America and Madagascar, respectively, but they are widely used as ornamental plants around the world (Singh and Kumar 2014; Santos et al. 2019). Their easily extractable galactomannans have been exploited as dietary fiber, fruit edible coating, preparation of mucoadhesive microspheres, drug delivery systems and injectable regenerative hydrogels (Cerqueira et al. 2009; Tamaki et al. 2010; Lima et al. 2010; Thombre and Gibe 2013; Buriti et al. 2014; Ogunjimi et al. 2017; Lima et al. 2019). Beneficial effects of these galactomannans were recently reported in rodent models of gastritis and osteoarthritis (Marques et al. 2019; Nascimento et al. 2021). Following international protocols preconized by Organization for Economic Co-operation and Development (OECD), this study evaluated the occurrence of systemic and local acute toxicity for these galactomannans in rats.

Methods

Seeds collection
Seeds of *Delonix regia* and *Caesalpinia pulcherrima* were collected in Limoeiro do Norte, Ceará, Brazil. The plants were identified at the Laboratory of Taxonomy of Angiospermae (Department of Biology/Federal University of Ceará) and the voucher specimens deposited at the Prisco Bezerra Herbarium / Federal University of Ceará (numbers 57951 and 57952, respectively). In accordance to the Brazilian Federal Law No. 13123/2015, the assessment activity was registered at the National System for the Management of the Genetic Heritage and the Associated Traditional Knowledge (SISGEN), code A54ED41.

**Isolation and chemical characterization of the galactomannans**

Galactomannans from *C. pulcherrima* (GM-CP) and *D. regia* (GM-DR) were isolated following the procedures respectively proposed by Marques et al. 2019 and Nascimento et al. 2021. Characterization were also done by such authors, and their results are summarized below. For each Leguminosae specie, 50 g of seeds were swelled under water vapour (1 atm, 30 min). Manually-removed endosperms were hydrated overnight at 4°C, and homogenized with 500 mL of distilled water. The first supernatant was collected after an overnight period of decantation. Remaining fragments were resubmitted to homogenization, and a second supernatant was collected. Both supernatants were mixed with two volumes of ethanol 96% (w/v), and the crude galactomannan was filtered under vacuum (glass filter no. 4), and dried at room temperature. Proteolysis was achieved by heating under reflux (85-90°C) of 1 g of crude sample in 200 ml of NaOH 5% (w/v) during 45 minutes under reflux. Alkali and low molar weight compounds were removed by dialysis against distilled water for 72 h, using a semipermeable cellulose membrane (cut off 10,000 g mol⁻¹). The dialysate was centrifuged for 15 minutes (1000 x g), and ethanol was added to the supernatant. The purified galactomannan was filtered under vacuum, and dried at room temperature until constant weight. Removal of proteins was confirmed in both samples through indetectable %N, using a 2400 Series II CHNS/O Elemental Analyzer. Thermogravimetric analysis revealed low levels of inorganic residues in the samples were found (0.24% for GM-CP and 0.56% for GM-DR). As expected for hygroscopic polyssacharides, moisture after desiccation was of 14.76% and 13.78%, respectively.

The purified samples displayed unimodal molar weigh distribution in high-performance size-exclusion chromatography performed at room temperature (Shimadzu equipment, PolySep-GFC-P Phenomenex, 35 mm x 7.80 mm and PolySep-GFC-P linear Phenomenex, 300 mm x 7.80 mm columns, 0.1 mol L⁻¹ NaNO₃ as eluent and flow rate of 0.5 mL min⁻¹). Using standard neutral pullulan samples (ShodexDenko™, 10³ - 10⁶ g mol⁻¹), peak molar weights were in the magnitude order of 10⁶ for GM-CP and 10⁵ g mol⁻¹ for GM-DR. FT-IR spectroscopy in KBr pellets revealed typical polysaccharides signals; for GM-CP: 3000–3490 cm⁻¹ of O-H, 1016–1074 cm⁻¹ of C-O (alcohol), 1159 cm⁻¹ of C-O-C glycosidic linkage and 2923 cm⁻¹ of C-H; for GM-DR: 3403 cm⁻¹ of O-H, 2920 cm⁻¹ of C-H, 1158 cm⁻¹ of C-O flexion in the pyranose ring, and the 1160-950 cm⁻¹ region, which includes signals for vibration of glycosidic C-O and C-O-C and primary alcohol C-O-H bonds. As determined through hydrolysis with trifluoroacetic acid, derivatization with pyridine and N,O-bis (trimethylsilyl) trifluoroacetamide, analysis in Shimadzu GC2014 Chromatograph (30 m x 0.25 mm x 0.25 µm capillary column, flow of nitrogen as at 4 kgf cm⁻²), GM-CP was composed by
mannose (64.5%), galactose (29.1%) and glucose (7.4%), whereas GM-DR contained mannose (64.5%),
galactose (27.0%) and glucose (8.4%); respective mannose:galactose ratios were of 2.18:1 and 2.39:1,
which were similar to those calculated by the intensity of signals at 4.73 ppm (H-1 of β-D-
mannopyranose) and 5.02 ppm (H-1 of α-D-galactopyranose) in 1H-NMR spectroscopy (Bruker DMX-500
spectrometer, D2O as solvent).

Animals

Female Wistar rats (170–200 g) were obtained from the Federal University of Ceará, and maintained
under padronized conditions (25 °C; cycle of 12 h light/12 h dark, and food and water ad libitum). The
procedures were conducted according to the guidelines of the National Council for the Control of Animal
Experimentation (CONCEA), under authorization by the ethics committee for animal research of the
Federal University of Ceará (No. 52120510/2018, see supplementary material S1).

Evaluation of systemic toxicity

The acute systemic toxicity of the galactomannans was evaluated according to OECD Guideline No.423
(2002). Groups of three animals were subjected to 2-hour fasting, and received a single dose (300 mg kg−1
per os) of the galactomannans from Caesalpinia pulcherrima (GM-CP) or Delonix regia (GM-DR). Fasting
was maintained until 2 hours after the administration. Since lethality was absent, other groups received
doses of 2,000 mg kg−1 (p.o.) Control group received vehicle (10 mL kg−1; sterile saline).

Body weight measurent was recorded during a 14-day period, as well the occurrence of toxicity signals by
the Malone's hippocratic screening (Malone and Robichaud 1962; Malone 1977). For evaluation
of exploratory activity, animals were acclimated during 1 minute in a 30 x 30 x 15 cm acrylic box with
transparent walls and black floor divided into 9 equal quadrants, and the exploratory activity measured by
the number of quadrant crossings, self-cleaning (grooming) and rearing during 5 minutes (Archer 1973).

Animals were euthanized under anesthesia (xyazine 10 mg kg−1 + ketamine 100 mg kg−1 i.p.) for blood
collection and removal of organs (kidneys, spleen, lungs, heart, liver and brain Counting of blood
figurative elements, as well cells volumes and hemoglobin content, were performed using an automated
hematology analyzer (SDH-3, Labtest, Brazil). Labtest Diagnostics Kits were used to measure serum
levels of urea, creatinine, total cholesterol, triglycerides, bilirubin, total proteins and albumin, and the
activity of the enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline
phosphate. Organ samples were embedded in paraffin, sectioned at 4-μm-thick sections for hematoxylin
&Eosin staining, and examined under light microscopy by an experienced pathologist without knowledge
of the treatments.

Evaluation of dermal toxicity

The dermal toxicity of the galactomannans was evaluated according to OECD Guideline No. 402 (2017)
in groups of three animals receiving the highest doses of galactomannans (2,000 mg kg−1 per os).
Animals had their thoracic dorsal area shaved one day before the experiment. Antisepsis was performed with 2% (w/v) chlorhexidine, and GM-CP or GM-DR (2,000 mg/kg, 0.3 mL) was uniformly applied in an area of 3 cm$^2$. Control group received vehicle (saline). Inoculated skin was covered with a porous gauze dressing and non-irritating tape throughout 24-hour exposure period. Occurrence of skin reactions (hyperemia and edema) were monitored during 14 days, using the Draize score system (Draize et al. 1944).

**Evaluation of intra-articular innocuity**

Occurrence of intra-articular pro-inflammatory reactions was verified in the right tibiotarsal joints of rat groups receiving GM-CP or GM-DR (200 µg / 25 µL; n=5). Control group received vehicle (saline). For comparison, galactomannan not-submitted to alkaline hydrolysis step were also tested (protein contents of 0.89% and 1.00%, respectively).

After injection, animals were individually placed into Plexiglas boxes with malleable mesh net floors, and joint flexion was achieved by pressing a large probe (4.15 mm$^2$) until the occurrence of paw withdrawal reflex. Reduced mechanical threshold is indicative of hypernociception (Bringel et al. 2020). The test was performed from hour 0 (immediately before the inoculation) to hour 6, in which animals were euthanized. Joint cavity was washed twice with 0.1 ml PBS containing 10 mmol L$^{-1}$ EDTA, and exudates were collected for total and differential cell counts using Neubauer chambers and stained smears, respectively.

**Statistical analysis**

Results were expressed as mean ± SEM. Statistical differences between parametric data were determined by one-way / two-way analysis of variance (ANOVA), followed by the Bonferroni’s test. Non-parametric data were expressed as median (IQR) and analysed by the Kruskal-Wallis’s test, followed by the Dunn’s test. P <0.05 was considered significant. All data is available as supplementary material.

**Results**

**Acute oral toxicity of the galactomannans**

No deaths were observed after the oral administration of the galactomannans, which demonstrates an LD50 greater than 2,000 mg kg$^{-1}$. Higher-doses of galactomannans had similar increase in body weight, as compared to the vehicle (GM-CP: + 1.0%; GM-DR: + 1.0%; control: + 2.75%, p>0.05) (Table 1).

Animals did not display alterations related to the central, somatosensory or autonomous nervous systems, as seen using the Malone’s Hippocratic triage (Table 2). In all groups, it was observed normal respiration, vibrissae movement, lacrimation and salivation, but no signals of cyanosis, piloerection, analgesia / sedation, ataxia, prostration, catatonia, tail erection, stereotyped movements, tremors nor convulsion. Although exophthalmos seemed to be present at day 14 in the GM-DR group, and in various
milestones in the GM-CP group (60 min, day 7 and day 14), it was also found in the vehicle-treated after 60 min.

In all groups, the exploratory activity has decreased along the experiment (Fig. 1). The time of observation significantly influenced the data variability for crossings and rearings (p=0.0241 and 0.0354, respectively), but not for groomings (p=0.2274). The treatments effect was not significant for such parameters (p>0.05).

No treatment-related gross pathological change was observed in the brain, liver, kidneys, heart, lungs and spleen (Table 3). Hystopathological alterations were also absent in such organs (Fig. 2), and no changes were detected on serum levels of the creatinine/urea and ALT/AST (Table 4). All groups displayed high blood glucose triglycerides levels, with significant hyperglycemia in the GM-DR group (+38.5% and +39.5% in comparison to control group, respectively). Other serum parameters remained unaltered, as well the hematological parameters (Table 5).

**Dermal toxicity of the galactomannans**

Topical application of *C. pulcherrima* or *D. regia* galactomannans did not evoke significant signals of skin irritation at 2,000 mg kg\(^{-1}\) (Table 6). When measured 24 h or 7 days after induction, the Draize's scores values for hyperemia were slightly higher in the GM-CP and GM-DR groups, but they did not reach statistical significance, in comparison to the vehicle-treated group. On the other hand, no signals of edema were observed at any endpoint.

**Intra-articular innocuity of the galactomannans**

As compared to the control group (vehicle), the intra-articular administration of unpurified samples of GM-CP and GM-DR evoked both mechanical hypernociception and inflammatory cell influx (GM-CP: 18.6±3.0 g and 11,060 ± 3,835 cells mm\(^{-3}\); GM-DR: 15.1±4.1 g and 23,680 ± 4,984 cells mm\(^{-3}\); control: 47.6±6.1 g and 151± 44 cells mm\(^{-3}\); p<0.05 vs. control) (Fig. 3). Neutrophils were the predominant in those inflammatory exsudates (>85%) (data not shown). On the other hand, administration of protein-free galactomannans was unable to cause adverse reactions (GM-CP: 38.0± 4.6 g and 41±18 cells mm\(^{-3}\); GM-DR: 47.3±9.5 g and 121±77 cells mm\(^{-3}\), p>0.05 vs. control).

**Discussion**

Safety of chemical compounds is an important issue for food or biomedical applications, and the conduction of acute toxicity studies has as the main objective the identification of side effects. In this study, bioactive and well-characterized galactomannans from *Caesalpinia pulcherrima* and *Delonix* had their acute toxicity systematically evaluated in rodents by the use of international preconized protocols, which comprises the administration of single initial doses of 300 mg kg\(^{-1}\) and a 14-day observation period.
As previously reported for others galactomannans, such as those of *Senna tora* and *Trigonella foenum-graecum* (Pawar and Lalith 2015; Deshpande et al. 2016), no lethality was observed among the animals treated with GM-CP or GM-DR, even at 2,000 mg kg\(^{-1}\). Despite Suryawanshi et al. (2015) had already reported similar evidence for the *C. pulcherrima* galactomannan, such study did not investigate impairments on target organs or biochemical and haematological parameters, as we did (see below). Additionally, animals did not display alterations of spontaneous locomotory activity (Prut and Belzung 2003) or in the nervous systems. Although toxic reactions could alter the body weight (Teo et al. 2002), such parameter was not significantly different among the groups along the 14-day period.

Structural and weight changes in organs may reflect toxicity due to several factors, including changes in the enzyme activity, injuries and other physiological disorders, which are dependent on target organs, and make possible the knowledge of the general health status of the animals (Auletta 1995; Michael et al. 2007). No macroscopic lesions or weight organs alterations were induced by the galactomannans on vital organs. Nevertheless, functional events may arise prior to morphological damage, especially in organs such kidneys and liver (Ramaiah 2011; Alimba et al. 2012), but the serum levels of the creatinine/urea and ALT/AST were normal for the animals euthanized 14 days after the acute administration of galactomannans. Moreover, substances affecting bone marrow could inhibit certain steps in the production of hemoglobin, and reduce the ability of the blood to distribute oxygen throughout the body (Jain et al. 2009). Both galactomannans tested did not change the haematological parameters, so that erythrocytes were both normocytic and normochromic. However, animals in all groups displayed high blood glucose levels (>140 mg dL\(^{-1}\)), even in the control group. Such values of post-brandial capillary glycemia are not uncommon, especially when blood collection is taken after zylaxine/ketamine anesthesia (Saha et al. 2005; Wang et al. 2010), so that such hyperglycemia may not be due to the treatment with the galactomannan.

As evaluated using the Draize's scoring system, cutaneous administration of GM-CP or GM-DR did not cause hyperemia or edema at 2,000 mg kg\(^{-1}\) and these findings agree with previous reports for innocuity of leaf polysaccharides of *D. regia* (Shewale et al. 2011; Wang et al. 2016). Regarding the intra-articular innocuity, the protein-free galactomannans did not evoke articular hypernociception or leukocyte influx. Similar to reported for the guar galactomannan (Castro et al. 2007), joint inflammatory responses were evoked solely by unpurified samples containing remaining proteins.

In conclusion, the lack of systemic and local reactions revealed that the seed galactomannan of *C. pulcherrima* and *D. regia* did not cause acute toxicity, and their LD50 values were superior to 2,000 mg kg\(^{-1}\), being allocated in the class 5 of the Globally Harmonised System for Classification and Labelling of Chemicals (GHS) (UN, 2019). Further assessments involving different administration schemes, such as repetitive doses, and evaluations in humans are recommended for their safe consumption.

Declarations
Ethical approval This study was performed in accordance with the guidelines of the Brazilian Council of Control in Animal Experimentation (CONCEA). Approval was granted by the local ethics committee (No. 52120510/2018; October 22\textsuperscript{nd}, 2018). Certificate is available as supplementary material.

Consent to participate Not applicable

Consent to publish Publication is consented by all authors.

Authors contribution RRC, EMCC and OVOM conceived and designed the research. FCJM, FGSN, DTTN and ICL conducted the experiments. PMGS and MRLM performed the histopathological analysis. AON and GFA performed the hematological and biochemical analyses. RRC and AMSA wrote the manuscript. All authors read and approved the manuscript and all data were generated in-house and that no paper mill was used.

Funding The authors would like to thank the Fundação Cearense de Apoio ao Desenvolvimento Científico e Tecnológico – FUNCAP (No. BP1-0067-00139.01.00/12) and the Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq (No. PQ - 308433/2017-3) for the financial support.

Competing interests The authors declare no conflict of interest.

Availability of data and material Availability is consented by all authors. All data is available as supplentary material.

Acknowledgement

The authors would like to thank Profa. Dra. Judith Pessoa Andrade Feitosa (Federal University of Ceará, Brazil) for the support during the characterization of the polysaccharides.

References

Alimba CG, Bakare AA, Aina OO (2012) Liver and kidney dysfunction in wistar rats exposed to municipal landfill leachate. Resources and Environment 2:150–163. https://doi.org/10.5923/j.re.20120204.04

Archer J (1973) Tests for emotionality in rats and mice: a review. Animal Behaviour 21:205–235. https://doi.org/10.1016/S0003-3472(73)80065-X https://www.ncbi.nlm.nih.gov/pubmed/4578750

Auletta S (1995) Acute, subchronic, and chronic toxicology. In: Derelanko, M.J., Hollinger, M.A. (eds.) Handbook of Toxicology. Boca Raton, Florida: CRC Press, pp. 51-162. https://doi.org/10.1201/9781420042078

Bringel PHSF, Marques GFO, de Queiroz Martins MG, da Silva M, Nobre C, do Nascimento K S, Cavada BS, Castro RR, Assreuy MAS (2020) The lectin isolated from the alga Hypnea cervicornis promotes antinociception in rats subjected to zymosan-induced arthritis: involvement of cGMP signalization and
cytokine expression. Inflammation 43:1446-1454. https://doi.org/10.1007/s10753-020-01222-z
https://www.ncbi.nlm.nih.gov/pubmed/31212035

Buriti FCA, Santos KMO, Sombra, VG, Maciel JS, Sá DMAT, Salles HO, Oliveira G, De Paula RCM, Feitosa JPA, Moreira ACOM, Egito AS (2014) Characterization of partially hydrolysed galactomannan from Caesalpinia pulcherrima seeds as a potential dietary fibre. Food Hydrocolloids 35:512–521. https://doi.org/10.1016/j.foodhyd.2013.07.015

Castro RR, Feitosa JP, da Cunha PL, Rocha FAC (2007) Analgesic activity of a polysaccharide in experimental osteoarthritis in rats. Clinical Rheumatology 26:1312 –1319. https://doi.org/10.1007/s10067-006-0506-9 https://www.ncbi.nlm.nih.gov/pubmed/17216398

Cerqueira MA, Pinheiro AC, Souza BWS, Lima AMP, Ribeiro C, Miranda C, Teixeira JA, Moreira RA, Coimbra MA, Gonçalves MP, Vicente AA (2009) Extraction, purification and characterization of galactomannans from non-traditional sources. Carbohydrate Polymers 75: 408–414. https://doi.org/10.1016/j.carbpol.2008.07.036

Deshpande P, Mohan V, Thakurdesai P (2016) Preclinical safety evaluation of low molecular weight galactomannans based standardized fenugreek seeds extract. Excli J 15:446-459. https://doi.org/10.17179/excli2016-461 https://www.ncbi.nlm.nih.gov/pubmed/27822173

Draize JH, Woorard G, Calvery HO (1944) Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 82:377-390.

Jain N, Sharma P, Sharma N, Joshi SC (2009) Haemato-biochemical profile following sub acute toxicity of malathion in male albino rats. Avicenna Journal of Phytomedicine 2:500–506.

Johnson W Jr, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Jr JGM, Shank RC, Slaga TJ, Snyder PW, Andersen FA (2015) Safety Assessment of Galactomannans as Used in Cosmetics. Int J Toxicol 34:35-65. https://doi.org/10.1177/1091581815586798 https://www.ncbi.nlm.nih.gov/pubmed/26227890

Lima AM, Cerqueira MA, Souza BWS, Santos ECM, Teixeira JA, Moreira RA, Vicente AA (2010) New edible coatings composed of galactomannans and collagen blends to improve the postharvest quality of fruits – Influence on fruits gas transfer rate. Journal of Food Engineering 97; 101–109. https://doi.org/10.1016/j.jfoodeng.2009.09.021

Lima EL, Vasconcelos NF, Maciel JS, Andrade KF, Silveira RV, Andrade JPF (2019) Injectable hydrogel based on dialdehyde galactomannan and N-succinyl chitosan: a suitable platform for cell culture. J Mater Sci Mater Med 31:5-13. https://doi.org/10.1007/s10856-019-6343-6 https://www.ncbi.nlm.nih.gov/pubmed/31832856
Malone MH, Robichaud RC (1962) A Hippocratic screen for pure or crude drug materials. Lloydia 25:320–332.

Malone MH (1977) Pharmacological approaches to natural product screening and evaluation. In: H. Wagner and P. Wolff (eds.) New Natural Products and Plant Drugs with Pharmacological, Biological or Therapeutical Activity, New York, USA: Springer-Verlag, pp 23-53. https://doi.org/10.1007/978-3-642-66682-7_2

Marques FCJ, Pantoja PS, Matos VEA, Silva RO, Damasceno SRB, Franco AX, Alves RC, Justino PFC, Souza MHLP, Feitosa JPA, Castro RR, Soares PMG (2019) Galactomannan from the seeds of Caesalpinia pulcherrima prevents indomethacin-induced gastrointestinal damage via neutrophil migration. International Journal of Biological Macromolecules 141: 68–75. https://doi.org/10.1016/j.ijbiomac.2019.08.193 https://www.ncbi.nlm.nih.gov/pubmed/31446106

Meer G, Meer WA, Tinker J (1975) Water-soluble gums: their past, present and future. Food Technology 29:26–8.

Michael B, Yano B, Sellers R. S, Perry R, Morton D, Roome N, Johnson JK, Schafer K, Pitsch S (2007) Evaluation of organ weights for rodent and non-rodent toxicity studies: A review of regulatory guidelines and a survey of current practices. Toxicologic Pathology 35:742–750. https://doi.org/10.1080/01926230701595292 https://www.ncbi.nlm.nih.gov/pubmed/17849357

Nascimento FGS, Bringel PHSF, Maia FWS, Lima CPC, Alves RC, Feitosa JPA, Mota MRL, Assreuy AMS, Castro RR (2021) Galactomannan of Delonix regia seeds reduces nociception and morphological damage in the rat model of osteoarthritis induced by sodium monoiodoacetate. Naunyn Schmiedebergs Arch Pharmacol 394:491-501. https://doi.org/10.1007/s00210-020-01996-x https://www.ncbi.nlm.nih.gov/pubmed/33057779

OECD (2002) Test No. 423: Acute Oral toxicity - Acute Toxic Class Method, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing, Paris. https://doi.org/10.1787/9789264071001-en. Accessed 2 May 2019

OECD (2017) Teste No. 402: Acute Dermal Toxicity, OECD Guidelines for the Testing of Chemicals, Seção 4, OECD Publishing, Paris. https://doi.org/10.1787/9789264070585-en. Accessed 16 March 2019

Ogunjimi AT, Melo SMG, Vargas-Rechia CG, Emery FS, Lopez RFV (2017) Hydrophilic polymeric nanoparticles prepared from Delonix galactomannan with low cytotoxicity for ocular drug delivery. Carbohydrate Polymers 157:1065–1075. https://doi.org/10.1016/j.carbpol.2016.10.076 https://www.ncbi.nlm.nih.gov/pubmed/27987808

Pawar AH, Lalith KG (2017) Toxicological Evaluation of Gum (Galactomannans) Isolated from Senna tora Seeds. J Drug Metabol Toxicol 6:1-5. https://doi.org/10.4172 / 2157-7609.1000193
Prajapati VD, Jani GK, Maradiya NG, Randeria NP, Nagar BJ, Naikwadi NN, Bhavesh C Variya BC (2013) Galactomannan: a versatile biodegradable seed polysaccharide. Int J Biol Macromol 60:83-92. https://doi.org/10.1016/j.ijbiomac.2013.05.017 https://www.ncbi.nlm.nih.gov/pubmed/23707734

Prut L, Belzung C (2003) The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. European Journal of Pharmacology 463:3–33. https://doi.org/10.1016/s0014-2999(03)01272-x https://www.ncbi.nlm.nih.gov/pubmed/12600700

Ramaiah SK (2011) Preclinical safety assessment: current gaps, challenges, and approaches in identifying translatable biomarkers of drug-induced liver injury. Clinics in Laboratory Medicine 31: 161–172. https://doi.org/10.1016/j.cll.2010.10.004 https://www.ncbi.nlm.nih.gov/pubmed/21295728

Saha JK, Xia J, Grondin JM, Engle SK, Jakubowski JA (2005) Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical models. Exp Biol Med (Maywood) 10:777–784. https://doi.org/10.1177/153537020523001012 https://www.ncbi.nlm.nih.gov/pubmed/16246906

Santos PLF, Castilho RMM, Pinheiro RR (2019) Seed position and influences on Caesalpinia pulcherrima germination and reserve proteins. Ornamental Horticulture 25:119-125. https://doi.org/10.14295/oh.v25i2.1727

Shewale VD, Deshmukh AT, Patil SL, Patil VR (2011) Anti-Inflammatory activity of Delonix regia (Boj. Ex. Hook). Advances in Pharmacological Science 5:1-4. https://doi.org/10.1155/2012/789713 https://www.ncbi.nlm.nih.gov/pubmed/22110490

Singh S and Kumar SN (2014) A review: introduction to genus Delonix. World Journal of Pharmacy and Pharmaceutical Sciences 3:2042-2055.

Srivastava M, Kapoor VP (2005) Seed galactomannans: an overview. Chemistry and Biodiversity 2:295–317. https://doi.org/10.1002/cbdv.200590013 https://www.ncbi.nlm.nih.gov/pubmed/17191982

Suryawanshi SR, Thakare NP, More DP, Thombre NA (2015) Bioavailability enhancement of ondansetron after nasal administration of Caesalpinia pulcherrima-based microspheres. Drug Delivery 22:894–902. https://doi.org/10.3109/10717544.2013.860205 https://www.ncbi.nlm.nih.gov/pubmed/24279581

Tamaki Y, Teruya T and Tako M (2010) The chemical structure of galactomannan isolated from seeds of Delonix regia. Biosc Biotechnol Biochem 74:1110-1112. https://doi.org/10.1271/bbb.90935 https://www.ncbi.nlm.nih.gov/pubmed/20460705

Teo S, Stirling D, Thomas S, Kiropes A, Khetani V (2002) A 90-day oral gavage toxicity study of d-methylphenidate and dl0-methylphenidate in Sprague–Dawley rats. Toxicology 179:183–196. https://doi.org/10.1016/s0300-483x(02)00338-4 https://www.ncbi.nlm.nih.gov/pubmed/12270592
Table 1 Systemic administration GM-CP and GM-DR does not alter the body weight of female rats

| Timepoint | Body weight (g) |
|-----------|----------------|
|           | Control | GM-CP | GM-DR |
| 60 min    | 182± 4  | 182± 3 | 184± 7 |
| Day 7     | 183± 3  | 182± 4 | 186± 7 |
| Day 14    | 187± 5  | 185± 5 | 186± 7 |

GM-CP = galactomannan from *C. pulcherrima* seeds (2,000 mg kg⁻¹ p.o.), GM-DR = galactomannan from *D. regia* seeds (2,000 mg kg⁻¹ p.o.). Mean ± SEM (n = 3 / group).

Table 2 Systemic administration of GM-CP and GM-DR does not alter the behavioral profile of female rats
| Parameters         | Control | GM-CP | GM-DR |
|--------------------|---------|-------|-------|
|                    | 60 min  | day 7 | day 14 | 60 min | day 7 | day 14 | 60 min | day 7 | day 14 |
| Ataxia             | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Analgesia          | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Catatonia          | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Convulsions        | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Cyanosis           | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Diarrhoea          | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Diuresis           | N       | N     | N     | N      | N     | N     | N      | N     | N     |
| Escape reaction    | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Exophthalmus       | P       | -     | -     | P      | P     | P     | P      | -     | P     |
| Grooming           | N       | N     | N     | N      | N     | N     | N      | N     | N     |
| Lacrimation        | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Motor activity     | N       | N     | N     | N      | N     | N     | N      | N     | N     |
| Paw licking        | N       | N     | N     | N      | N     | N     | N      | N     | N     |
| Piloeretion        | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Prostration        | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Respiration        | N       | N     | N     | N      | N     | N     | N      | N     | N     |
| Salivation         | N       | N     | N     | N      | N     | N     | N      | N     | N     |
| Sedation           | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Stereotyped        | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| movements          |         |       |       |        |       |       |        |       |       |
| Tail erection      | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Tremors            | -       | -     | -     | -      | -     | -     | -      | -     | -     |
| Vibrissae movement | N       | N     | N     | N      | N     | N     | N      | N     | N     |

C. = control (vehicle) group, GM-CP = galactomannan from *C. pulcherrima* seeds (2,000 mg kg\(^{-1}\) p.o.), GM-DR = galactomannan from *D. regia* seeds (2,000 mg kg\(^{-1}\) p.o.). N= Normal, P = Present, - = Not found (n = 3 / group).

**Table 3** Systemic administration of GM-CP and GM-DR does not alter the organs weight of female rats
| Organ       | Weight (g) | Control     | GM-CP       | GM-DR       |
|-------------|------------|-------------|-------------|-------------|
| Brain       | 1.84 ± 0.06| 1.93 ± 0.03 | 1.86 ± 0.14 |
| Heart       | 0.74 ± 0.06| 0.69 ± 0.02 | 0.73 ± 0.02 |
| Kidneys     | 1.43 ± 0.07| 1.52 ± 0.07 | 1.37 ± 0.03 |
| Liver       | 6.54 ± 0.19| 6.28 ± 0.01 | 6.01 ± 0.38 |
| Lungs       | 1.67 ± 0.18| 1.51 ± 0.13 | 1.56 ± 0.11 |
| Spleen      | 0.56 ± 0.06| 0.50 ± 0.03 | 0.53 ± 0.04 |

GM-CP = galactomannan from *C. pulcherrima* seeds (2,000 mg kg\(^{-1}\) p.o.), GM-DR = galactomannan from *D. regia* seeds (2,000 mg kg\(^{-1}\) p.o.). Mean ± SEM (n = 3 / group).

**Table 4** Systemic administration GM-CP and GM-DR does not alter serum markers of female rats

| Parameter                  | unit       | Control     | GM-CP       | GM-DR       |
|----------------------------|------------|-------------|-------------|-------------|
| Alkaline phosphatase       | U/L        | 70± 34      | 136 ± 53    | 70± 12      |
| ALT                        | U/L        | 95 ± 4      | 74 ± 2      | 74 ± 13     |
| AST                        | U/L        | 28 ± 3      | 35 ± 1      | 33 ± 2      |
| Albumin                    | mg dL\(^{-1}\)| 4.53 ± 0.34 | 5.14 ± 0.29 | 5.41 ± 0.19 |
| Bilirubin                  | mg dL\(^{-1}\)| 0.07 ± 0.03 | 0.04 ± 0.03 | 0.20 ± 0.10 |
| Creatinine                 | mg dL\(^{-1}\)| 0.66 ± 0.02 | 0.67 ± 0.10 | 0.57 ± 0.03 |
| Glucose                    | mg dL\(^{-1}\)| 143 ± 14    | 182 ± 4     | 198±8*      |
| Protein                    | mg dL\(^{-1}\)| 10.83 ± 0.00| 11.93 ± 0.43| 11.50 ± 0.34|
| Total cholesterol          | mg dL\(^{-1}\)| 62± 4       | 68 7        | 68 ± 9      |
| Tryglicerides              | mg dL\(^{-1}\)| 128±1       | 119±14*     | 137±2.      |
| Urea                       | mg dL\(^{-1}\)| 75± 2       | 78± 3       | 69± 3       |

GM-CP = galactomannan from *C. pulcherrima* seeds (2,000 mg kg\(^{-1}\) p.o.), GM-DR = galactomannan from *D. regia* seeds (2,000 mg kg\(^{-1}\) p.o.). Mean ± SEM (n = 3 / group). *P<0.05 vs. Control (ANOVA, Bonferroni)

**Table 5** Systemic administration of GM-CP and GM-DR does not alter the hematological parameters of female rats
### Parameters

| Parameters                  | Unit       | Control       | GM-CP         | GM-DR         |
|-----------------------------|------------|---------------|---------------|---------------|
| **Red Blood Cells**         | $x 10^6 \mu L^{-1}$ | 8.41±0.14     | 8.24±0.10     | 8.10±0.16     |
| Hemoglobin                  | g dL$^{-1}$ | 14.0±0.83     | 13.8±0.1      | 13.8±0.1      |
| Hematocrit                  | %          | 49.71±0.39    | 48.38±0.40    | 45.3±1.78     |
| MCV                         | fL         | 60±0          | 58±0          | 59±1          |
| MCH                         | pg         | 16.6±0.3      | 16.8±0.3      | 17.1±0.3      |
| MHCH                        | g dL$^{-1}$ | 28.0±0.4      | 28.5±0.2      | 30.6±1.4      |
| RBC distribution            | %          | 14.0±0.2      | 15.5±0.8      | 137±0.6       |
| **Platelets**               | $x 10^3 \mu L^{-1}$ | 1784±86       | 1789±22       | 1658±100      |
| Platelet Mean Volume        | fL         | 7.2±0.1       | 7.0±0.1       | 7.2±0.1       |
| Platelet distribution       | %          | 36.1±0.5      | 36.0±0.5      | 36.0±1.20     |
| **Leukocytes (total count)**| $x 10^3 \mu L^{-1}$ | 10.41±1.36    | 9.36±1.64     | 8.43±0.30     |
| Granulocytes                | $x 10^3 \mu L^{-1}$ | 2.01±0.38     | 1.66±0.51     | 0.80±0.05     |
| Lymphocytes                 | $x 10^3 \mu L^{-1}$ | 7.74±1.05     | 6.98±0.73     | 6.93±0.33     |
| Monocytes, basophiles and eosinophiles | $10^3 \mu L^{-1}$ | 0.66±0.05     | 0.63±0.10     | 0.69±0.08     |

GM-CP = galactomannan from *C. pulcherrima* seeds (2,000 mg kg$^{-1}$ p.o.), GM-DR = galactomannan from *D. regia* seeds (2,000 mg kg$^{-1}$ p.o.). MCH = mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; MCV = mean corpuscular volume; RBC = red blood cells distribution. Mean ± SEM (n = 3 / group).

**Table 6** Topical administration of galactomannans of GM-CP and GM-DR does not evoke skin reactions in female Wistar rats
| Reaction | Control | GM-CP | GM-DR |
|----------|---------|-------|-------|
| **Hyperemia** |         |       |       |
| 24 h     | 0 (0-2) | 1 (1-2) | 1 (0-1) |
| Day 7    | 0 (0-1) | 1 (1-2) | 1 (0-1) |
| Day 14   | 0 (0-1) | 0 (0-1) | 0 (0-0) |
| **Edema** |         |       |       |
| 24h      | 0 (0-2) | 0 (0-1) | 0 (0-1) |
| Day 7    | 0 (0-0) | 1 (0-1) | 0 (0-0) |
| Day 14   | 0 (0-0) | 0 (0-0) | 0 (0-0) |

GM-CP = galactomannan from *C. pulcherrima* seeds (2,000 mg kg\(^{-1}\) p.o.), GM-DR = galactomannan from *D. regia* seeds (2,000 mg kg\(^{-1}\) p.o.). Mean ± SEM (n = 3 / group).

**Figures**
Systemic administration GM-DR or GM-DR does not alter the exploratory activity of female rats. Animals received vehicle (control, □) or galactomannans – (GM-CP, ■) / (GM-DR, ■) (2,000 mg kg⁻¹ p.o.). Mean ± SEM (n=3 / group) for number of crossings (a), rearings (b) and groomings (c). GM-CP = galactomannan of C. pulcherrima seeds; GM-DR = galactomannan of D. regia seeds

Figure 1
Figure 2

The purified galactomannans GM-DR or GM-DR do not evoke mechanical hypernociception (a, b) or leukocyte influx (c, d) in tibiotarsal joints of female rats. Mean ± SEM (n = 5/group). *p<0.05 vs. control (vehicle); #P<0.05 vs. unpurified galactomannan (ANOVA, Bonferroni). GM-CP = galactomannan of C. pulcherrima seeds; GM-DR = galactomannan of D. regia seeds
Figure 3

Photomicrographs of tissues from female rats treated with GM-DR or GM-DR. (a) Spleen with normal architecture (capsule, red and white pulps). (b) Brain, showing a normal section with the central channel surrounded by the substantia cinza. (c) Heart. (d) Lung with normal alveolar sacs (arrow) (e) Liver with hepatocytes arranged in thin plates and sinusoids (arrow). (f) Kidney with normal architecture of proximal tubules (arrow) and absence of inflammation or necrosis. H&E staining. Magnification of 100 x
(a, b, c) or 400 x (d, e, f). vehicle= control group, GM-CP = galactomannan of C. pulcherrima seeds (2,000 mg kg-1 p.o.), GM-DR = galactomannan of D. regia seeds (2,000 mg kg-1 p.o.)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Ethicscertificate2018.pdf
- NaunynGMtoxicitydata.xlsx